# A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection

> **NCT02573857** · PHASE1,PHASE2 · TERMINATED · sponsor: **Medicines for Malaria Venture** · enrollment: 16 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** DSM265
- **DRUG:** OZ439

## Key facts

- **NCT ID:** NCT02573857
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-06-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02573857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02573857, "A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02573857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*